Elonva Market Report 2026

Elonva Market Overview

• The Elonva market growth in the historic period has been driven by increasing infertility prevalence, clinical success of assisted reproduction • Market expansion is supported by delayed parenthood trends, rising demand for ivf cycles • Growth Driver: Rising Prevalence Of Ovarian Disorders Drives Growth Of The Market • Market Trend: Expanding Access For Platinum-Resistant Ovarian Cancer And Assisted Reproductive Technology • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Elonva Market?

Elonva (corifollitropin alfa) is a fertility medication used in assisted reproductive treatments such as in vitro fertilization (IVF) to stimulate the ovaries and promote the growth of multiple follicles. Elonva is a long-acting formulation that requires only a single injection to initiate ovarian stimulation, reducing the need for daily hormone shots. This helps improve the chances of successful pregnancy in women with fertility challenges by providing a more controlled and convenient approach to ovarian stimulation. The main clinical indications in the elonva market are in vitro fertilization (IVF), hypogonadotropic hypogonadism in adolescent males, and ovarian hyperstimulation syndrome (OHSS) management. In vitro fertilization (IVF) is a medical procedure used to help individuals and couples conceive a child by fertilizing an egg with sperm outside the body in a laboratory setting. The various distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies, and different end users encompass fertility clinics, hospitals, research institutes, and others.

What Is The Elonva Market Growth Forecast?

The growth in the forecast period can be attributed to delayed parenthood trends, rising demand for ivf cycles, technological advances in fertility drugs, growing healthcare access in emerging markets, favorable reimbursement expansion. Major trends in the forecast period include single injection ovarian stimulation protocols, rising ivf procedure volumes, shift toward patient friendly fertility treatments, improved controlled ovarian response outcomes, growth of long acting gonadotropins.

Global Elonva Market Segmentation

1) By Clinical Indication: In Vitro Fertilization (IVF), Hypogonadotropic Hypogonadism in Adolescent Males, Ovarian Hyperstimulation Syndrome (OHSS) Management 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Fertility Clinics, Hospitals, Research Institutes, Other End Users

What Are The Drivers Of The Elonva Market?

The rising prevalence of ovarian disorders is expected to boost the growth of the elonva market going forward. Ovarian disorders are attributed to various factors, including hormonal imbalances, genetic mutations (such as BRCA1 and BRCA2), polycystic ovary syndrome (PCOS), autoimmune conditions, environmental factors such as exposure to toxins, and lifestyle choices such as obesity and smoking. Elonva helps treat ovarian disorders by stimulating the ovaries to produce multiple follicles, improving the chances of successful pregnancy in women with fertility issues such as polycystic ovary syndrome (PCOS) or unexplained infertility. For instance, in 2024, the American Cancer Society, a US-based non-profit cancer advocacy organization, reported that 19,680 new cases of ovarian cancer were diagnosed in the US, and 12,740 women died from the disease. Thus, the rising prevalence of ovarian disorders is driving the growth of the elonva industry. The rising infertility rate is expected to propel the growth of the elonva market going forward. Infertility rates refer to the frequency of conditions where individuals or couples are unable to achieve pregnancy after 12 months or more of regular, unprotected sexual intercourse. The rising infertility rate is primarily attributed to factors such as delayed childbearing, lifestyle changes, environmental toxins, and health conditions such as obesity and diabetes. Elonva minimizes infertility by improving ovarian stimulation with a single injection that encourages the ovaries to produce multiple follicles, enhancing the chances of a successful pregnancy for women undergoing assisted reproductive technologies such as in vitro fertilization (IVF). For instance, in April 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 17.5% of the global adult population, or about 1 in 6 individuals, face infertility. Thus, the rising infertility rate is driving the growth of the elonva industry.

Key Players In The Global Elonva Market

Major companies operating in the elonva market are Merck & Co. Inc.

Global Elonva Market Trends and Insights

The key trend in the elonva market is the focus on securing approvals to broaden the treatment's availability for patients with platinum-resistant ovarian cancer. This effort aims to meet the demand for advanced, targeted therapies for patients facing this difficult and frequently treatment-resistant type of ovarian cancer. For instance, in January 2023, Merck & Co., Inc., a US-based pharmaceutical company, received European Commission approval for Elonva, which is indicated for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART). This approval allows for unified labeling across all European Union member states, simplifying access for healthcare providers and patients. Elonva is notable for its ability to replace the first seven daily injections of conventional follicle-stimulating hormone (FSH) with a single subcutaneous injection, significantly reducing the treatment burden for women trying to conceive.

Regional Insights

North America was the largest region in the elonva market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Elonva Market?

The elonva market consists of sales of corifollitropin alfa injectable formulations and hormonal combination treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Elonva Market Report 2026?

The elonva market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the elonva industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.